A new drug designed to counter the effects of an important, but very hard to target, cancer mutation could be effective against a range of tumour types including lung and gynaecological cancers, a new clinical trial shows.

Lung cancer in non-smokers is a biologically distinct disease from that in smokers, according to a new study. Researchers also found it has characteristics that mean it could be targeted with tailored treatments.

A personalised cancer vaccine, used in combination with an immunotherapy drug, triggers a response from the immune system that is specific to the cancer and shows some clinical benefit, according to the results of an early clinical trial presented at the virtual AACR conference.